Home » Topics » Disease categories and therapies » Inflammatory

Inflammatory
RSS

MAP3K5 inhibitors identified by Fujian Cosunter Pharmaceutical Co., Medshine Discovery

Aug. 13, 2018

Uncovering the function of Cep57 in mosaic-variegated aneuploidy syndrome

Aug. 13, 2018

BRD4 inhibitors patented by Luoxin Biotechnology Shanghai, Shandong Luoxin Pharmacy Group

July 30, 2018

Vasopressin inhibition decreases mortality in jet-lagged mice

July 24, 2018

Fixing nuclear transport helps cells cope with premature, normal aging

July 11, 2018

Celtaxsys divulges new LTA-4 hydrolase inhibitors

July 5, 2018

Thinning out fat cells

July 2, 2018

Brain sleepiness signature, links to memory identified

June 19, 2018

Roche patents anti-pY796-DDR1 antibodies

June 8, 2018

Secarna Pharmaceuticals patents novel anti-CD39 immunosuppression-reverting oligonucleotides

May 8, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.